Patents by Inventor Per Hertz Hansen

Per Hertz Hansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110124556
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: April 20, 2010
    Publication date: May 26, 2011
    Applicants: NOVO NORDISK A/S, ANTYRA INC.
    Inventors: RENUKA PILLUTLA, RENEE BRISSETTE, ARTHUR J. BLUME, LAUGE SCHAFFER, JAKOB BRANDT, NEIL I. GOLDSTEIN, JANE SPETZLER, SOREN OSTERGAARD, PER HERTZ HANSEN
  • Patent number: 7576059
    Abstract: A pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: August 18, 2009
    Assignee: Novo Nordisk A/S
    Inventors: Ib Jonassen, Svend Havelund, Per Hertz Hansen, Peter Kurtzhals, John B. Halstrøm
  • Publication number: 20090192072
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: November 21, 2008
    Publication date: July 30, 2009
    Applicants: Novo Nordisk A/S, Antyra Inc. (formerly DGI Bio Technologies)
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jacob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
  • Patent number: 7229964
    Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the ?-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.
    Type: Grant
    Filed: July 16, 2003
    Date of Patent: June 12, 2007
    Assignee: Novo Nordisk A/S
    Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
  • Patent number: 6875741
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: April 5, 2005
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schäffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Søren Østergaard, Per Hertz Hansen
  • Publication number: 20040067874
    Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.
    Type: Application
    Filed: July 16, 2003
    Publication date: April 8, 2004
    Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
  • Publication number: 20030236190
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: September 24, 2002
    Publication date: December 25, 2003
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jacob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
  • Publication number: 20030195147
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: September 24, 2001
    Publication date: October 16, 2003
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
  • Patent number: 6620780
    Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: September 16, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
  • Publication number: 20020193292
    Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.
    Type: Application
    Filed: May 21, 2001
    Publication date: December 19, 2002
    Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
  • Publication number: 20010016643
    Abstract: A pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.
    Type: Application
    Filed: January 30, 2001
    Publication date: August 23, 2001
    Inventors: Ib Jonassen, Svend Havelund, Per Hertz Hansen, Peter Kurtzhals, John B. Halstrom
  • Patent number: 6251856
    Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: June 26, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
  • Patent number: 5869602
    Abstract: The present invention relates to a pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: February 9, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Ib Jonassen, Svend Havelund, Per Hertz Hansen, Peter Kurtzhals, John Halstr.o slashed.m